Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolism Modulation, Colorectal Oncology, and ADC Payload Optimization.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UGT1A10 drug discovery and DMPK profiling. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Enzyme (Wild-Type) | UGT1A10 Recombinant Protein; High purity (>95%), Sequence Verified, HEK293 Expressed. Theoretical MW validated. Endotoxin <1EU/ug. | View UGT1A10 Products |
| Pharmacogenomic Panel | UGT1A10 Mutant Proteins (e.g., *2, *3, *5 variants); Polymorphic isoforms for DDI and toxicity studies. Sequence Verified. | View UGT1A10 Products |
| Antigen | UGT1A10 Recombinant Protein (alternative tag); High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View UGT1A10 Products |
| Benchmark Ab | Anti-UGT1A10 Antibody; Recombinant positive control for western blot and IHC. | View UGT1A10 Products |
| Gene Delivery | UGT1A10 Promise-ORF / Lentivirus; Full-length ORF for stable cell line construction in colon/liver cell models. | View UGT1A10 Products |
| Validator | UGT1A10 siRNA Set; For knockdown verification and specificity controls in metabolic assays. | View UGT1A10 Products |
| Related Target | UGT1A1; Hepatic SN-38 glucuronidation comparator; irinotecan metabolism partner enzyme. | View UGT1A1 Products |
| Related Target | UGT1A9; Hepatic/intestinal glucuronidation enzyme; cross-reactivity control for selective inhibitor screening. | View UGT1A9 Products |
| Related Target | UGT2B7; Morphine/zidovudine metabolizing enzyme; off-target panel member for selectivity assays. | View UGT2B7 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Polymorphic Variability (DDI Risk Assessment) | Wild-type + Major Variant Panel (*2, *3, *5) with Strict Sequence Verification; Native glycosylation pattern preserved in HEK293 expression. |
| Enzyme Kinetic Accuracy (SN-38 Glucuronidation) | High Purity (>95%) minimizes contaminating UGT isoform activity; Endotoxin Controlled for cell-based stability. |
| Isoform Selectivity (Avoid UGT1A1 Cross-inhibition) | Human UGT1A1/1A9/2B7 ortholog proteins available for parallel selectivity screening; Mass Spec Verified. |
| Lack of Specificity Controls | Validated siRNA included for target-specific knockdown confirmation; High-affinity antibodies provided for expression profiling. |
Live UGT1A10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The understanding of UGT1A10's role in extrahepatic glucuronidation is reshaping precision oncology and ADC development strategies. As a primary intestinal glucuronidation enzyme, UGT1A10 significantly influences the clearance of SN-38, the active metabolite of irinotecan and the payload for several antibody-drug conjugates (e.g., Trodelvy). The current R&D landscape focuses on UGT1A10 inhibition as a mechanism to enhance irinotecan bioavailability and reduce gastrointestinal toxicity (irinotecan-induced diarrhea). Major players (academic centers and DDI specialists) are shifting toward modulation of local intestinal drug concentrations. As first-generation pharmacogenomic studies correlate UGT1A10 polymorphisms with toxicity profiles, the next wave of development targets selective small-molecule inhibitors for combination with SN-38-based ADCs to optimize therapeutic windows. Additionally, prodrug strategies leveraging UGT1A10's high expression in colorectal tissue are emerging for targeted colon cancer therapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Oncology Biopharmas, Academic DDI Specialists | Irinotecan Toxicity Mitigation, Colorectal Cancer | Enzyme Kinetics Panel (Need WT + Mutant proteins for accurate IC50 determination against polymorphic variants) |
| Pharmacogenomic Biomarker | Diagnostic Companies (PGx Panels) | Cancer Chemotherapy Personalization | Variant Protein Library (*2, *3) for activity-genotype correlation studies |
| ADC Combination Therapy | ADC Developers (SN-38 Payload) | Solid Tumors (GI, Lung) | SN-38 Glucuronidation Assay (Need high-purity UGT1A10 to model intestinal first-pass metabolism) |
| Prodrug Activation | GI Specialists, Biotech Innovators | Targeted Colon Cancer Therapy, Inflammatory Bowel Disease | Substrate Specificity Profiling (Need active enzyme with correct glycosylation for prodrug screening) |
| Oral Biologics | Metabolic Pharmas | Systemic Delivery | Clearance Screening (Need Lentivirus for Stable Cell Lines) |
Pharmacogenomic Considerations & Key Variants
UGT1A10 exhibits clinically relevant polymorphisms that alter enzyme activity and impact drug toxicity. Based on UniProt evidence (Q9HAW8), key mutations include: rs56935833 (corresponding to variant *2, Asn33Lys), rs10187694 (*3, Val208Met), and rs58704432 (*5, frameshift). These variants, particularly *2 and *3, show reduced glucuronidation capacity for SN-38 and are associated with increased risk of irinotecan-induced diarrhea in Asian populations (allele frequency 5–10%). TarMart offers recombinant wild-type and variant proteins (*2, *3, *5) expressed in HEK293 to preserve native glycosylation, enabling accurate genotype–phenotype–toxicity correlation studies for DDI risk assessment and personalized chemotherapy.